IP Library Granted Patent US 9,937,134
Granted Patent B2
US 9,937,134 · App. 14/803,841 · Granted Apr 10, 2018

Hyaluronate compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,937,134
App. No.
14/803,841
Granted
Apr 10, 2018
Kind
B2
Abstract

The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for making and using the same.

Claims (20)

1. A composition suitable for topical administration to a mammalian subject, the composition comprising, by mass, from about 0.05% to about 5% sodium hyaluronate and a pharmaceutically acceptable excipient, wherein from about 0.001 wt % to about 5 wt % of the sodium hyaluronate in the composition has a molecular weight ranging between about 0.01 megadaltons and about 0.4 megadaltons and from about 0.001 wt % to about 5 wt % of the sodium hyaluronate in the composition has a molecular weight ranging between about 0.5 megadaltons and about 1.6 megadaltons;

and wherein the pharmaceutically acceptable excipient is predominantly in the liquid phase at ambient temperature.

2. The composition of claim 1 , wherein from about 50 wt % to about 95 wt % of the sodium hyaluronate in the composition has a molecular weight ranging between about 1.7 megadaltons and about 4.0 megadaltons.

3. The composition according to claim 1 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of water, an alcohol, an oil, glycerin, polyethylene glycol, lanolin, petrolatum, wax, and poloxamer.

4. The composition according to claim 3 , wherein the pharmaceutically acceptable excipient is alcohol selected from the group consisting of ethanol, benzyl alcohol, isopropyl alcohol, octyldodecanol, cetostearyl alcohol, and lanolin alcohol.

5. The composition according to claim 4 , wherein the ratio of the mass of water to the total mass of the composition is about 99.235%.

6. The composition according to claim 3 , wherein the pharmaceutically acceptable excipient is oil selected from the group consisting of almond oil, castor oil, com oil, cottonseed oil, light mineral oil, mineral oil, olive oil, peanut oil, polyoxyl 35 castor oil, sesame oil, soybean oil, and sunflower oil.

7. The composition according to claim 3 , wherein the pharmaceutically acceptable excipient is water.

8. The composition of claim 7 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 60% to about 99.9%.

9. The composition according to claim 7 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 90.0% to about 99.9%.

10. The composition according to claim 7 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 92.5% to about 99.8%.

11. The composition according to claim 7 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 95.0% to about 99.7%.

12. The composition according to claim 7 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 97.5% to about 99.6%.

13. The composition according to claim 7 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 98.5% to about 99.5%.

14. The composition according to claim 7 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 99.0% to about 99.4%.

15. The composition according to claim 7 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 99.2% to about 99.3%.

16. The composition of claim 1 , wherein the composition further comprises an antifungal agent.

17. The composition according to claim 16 , wherein the antifungal agent is selected from the group consisting of clioquinol, haloprogin, miconazole nitrate, povidone-iodine, tolnaftate, ketoconazole, undecylenic acid, butoconazole and clotrimazole.

18. The composition according to claim 17 , wherein the antifungal agent is clotrimazole.

19. The composition according to claim 1 , wherein the composition further comprises an antibiotic.

Assignments (3)
SECURITY INTEREST Recorded Dec 19, 2019
From: CURRAX PHARMACEUTICALS LLC; NALPROPION PHARMACEUTICALS LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 051377/0958 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2019
From: CYPRESS PHRAMACEUTICALS, INC.
To: CURRAX PHARMACEUTICALS LLC
Reel/Frame 049329/0945 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2015
From: PERNIX THERAPEUTICS HOLDINGS, INC.
To: CYPRESS PHARMACEUTICALS, INC.
Reel/Frame 036387/0660 →